The growth of global radiopharmaceutical market is attributed to the factors such as increase in the number of patients of cancer, dementia and Alzhimer’s Parkinson and increase in demand from developing countries attributed to non-invasiveness procedures.
The market of radiopharmaceuticals is dominated by diagnostic radioisotopes, comprising of SPECT and PET radioisotopes. The lions share of the SPECT market is taken up by Tc-99m, whereas the PET market is dominated by F-18FDG isotope.
marketreportslibrary.com has released a new "North American Nuclear Medicine or Radiopharmaceuticals Market" report for the upcoming year, that includes major growth is projected over the forecasting period.
The major players covered in the global radiopharmaceuticals market are Siemens Healthcare Private Limited, Bayer, GE Healthcare.... @ @ https://bit.ly/3xiqYIu
This report studies the global market size of Radiopharmaceuticals in Nuclear Medicine in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Radiopharmaceuticals in Nuclear Medicine in these regions.
The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021).
Global Diagnostic Radiopharmaceuticals & Contrast Media Market 2023 is an extensive, professional analysis bringing market research data which is pertinent to new market entrants and recognized players. The report covers data that makes the record a resource for analysts, managers, Diagnostic Radiopharmaceuticals & Contrast Media industry experts as well as important people to get self-analyze along with ready-to-access study together side graphs and tables. Mixing the information integration and research capacities with the findings, this Diagnostic Radiopharmaceuticals & Contrast Media report has forecast the strong rise of this market in product sections and every geography.
Diagnostic Radiopharmaceuticals & Contrast Media market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Diagnostic Radiopharmaceuticals & Contrast Media market will be able to gain the upper hand as they use the report as a powerful resource.
2018 Market Research Report on Radiopharmaceuticals was a professional and depth research report on Radiopharmaceuticals that you would know the world's major regional market conditions of Radiopharmaceuticals, the main region including North American, Europe and Asia etc., and the main country including United States ,Germany ,Japan and China etc..
Radiopharmaceuticals in Nuclear Medical market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Radiopharmaceuticals in Nuclear Medical market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on production capacity, revenue and forecast by Type and by Application for the period 2015-2026.
Global Radiopharmaceuticals Market, By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)– Industry Trends andForecast To 2024
This report studies the Asia-Pacific nuclear medicine market over the forecast period of 2012-2017. The Asia-Pacific radiopharmaceutical market was valued at $500.8 million in 2012 and is poised to reach $824.9 million by 2017 at a CAGR of 10.5%. Similar to the global nuclear medicine market, the Asia-Pacific region is also minimizing its dependency on nuclear reactor by introducing hospital-based cyclotron facilities. This paves the way for novel isotopes such as Tl-201, F-18, and Rb-82 to capitalize on opportunities in the growing diagnostics market. Besides the gigantic Tc-99m market, florbetapir F 18 and F18-FDG are gaining popularity through their applications for Alzheimer’s disease and diagnosis of brain tumors. Nihon Medi Physics, Covidien, Fujifilm, and ANSTO contributed more than 75 % to the APAC radiopharmaceuticals market in 2012.
The radioisotope and stable isotope markets have been segmented according to the type of isotope, and a pplications.Both of these markets are broken down into segments and sub-segments, providing exhaustive value analysis for the years 2010, 2011, 2012, and forecast to 2017. Each market is comprehensively analyzed at a granular level by country (Germany, France, Italy, Spain, U.K., Russia, and Rest of Europe) to provide in-depth information on the European scenario.
The global radiopharmaceuticals market size was valued at $5.2 billion in 2022, and is projected to reach $13.7 billion by 2032, growing at a CAGR of 10.2% from 2023 to 2032.
Global Radiopharmaceuticals Market According to Data Bridge Market Research new Market report– Industry Trends and Forecast is projected to reach USD 10.57 billion by 2025, at a CAGR of 9.0% during the forecast period of 2018 to 2025.
Radiopharmaceutical is a radioactive pharmaceutical agent which is used diagnostic or therapeutic procedures. A radiopharmaceutical is made up of two components that are drug component and radioactive component.
Radiopharmaceutical is a radioactive pharmaceutical agent which is used diagnostic or therapeutic procedures. A radiopharmaceutical is made up of two components that are drug component and radioactive component.
The global Radiopharmaceuticals/Nuclear Medicine Market was valued at US$ 5605 Million in 2022 and is anticipated to grow at US$ 9327 Million by 2029 recording a CAGR of 9.3% during the forecast period 2023-2029. Request sample report at https://www.precisionbusinessinsights.com/request-sample/?product_id=17441
Positron Emission Tomography Market report gives attention to market segmentation, market size, and forecast of 2023-2032 to help stakeholders in making a good decision for the future investments. Urinary Catheters industry report segmented into types, application, and regions with providing production, revenue, import/export.
The Radiopharmaceuticals Market is anticipated to witness substantial growth in the coming years. Rise in venture capital investments is anticipated to aid market growth
The global radiopharmaceuticals market was worth USD 4.31 Billion in 2020 and is further projected to reach USD 6.43 Billion by 2027, at a CAGR of 6.0% during 2021-2027 (forecast period).
The radiopharmaceuticals market is projected to reach US$ 13,818.17 million by 2028 from US$ 7,550.74 million in 2021; it is expected to grow at a CAGR of 9.0% from 2021 to 2028.
The radiotherapy market is projected to reach US$ 10,170.80 million by 2028 from US$ 6,474.78 million in 2020; it is estimated to grow at a CAGR of 5.9% from 2021 to 2028.
Global Radiopharmaceutical Theragnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Product Type, Radioisotope, Source, Application, Indication, and End User,” the market is expected to grow from US$ 1,814.58 million in 2022 to US$ 3,441.97 million by 2028; it is estimated to grow at a CAGR of 11.3% from 2022 to 2028
In the context of China-US trade war and global economic volatility and uncertainty, it will have a big influence on this market. Nuclear Medicine/Radiopharmaceuticals Report by Material, Application, and Geography Global Forecast to 2023 is a professional and comprehensive research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).
In-depth research of the Radiopharmaceuticals Market helps to provide the relevant emerging trends and growth opportunities – report given by TBRC. https://bit.ly/3mmqkmo
Latest research Radiopharmaceuticals Market, released by The Business Research Company with 130+ pages of analysis on business strategy and emerging industry players. https://bit.ly/3mmqkmo
Global Radiopharmaceuticals Market by The Business Research Company is segmented as Oncology, Cardiology, Gastroenterology, Neuroendocrinnology, Neurology https://bit.ly/3iywX58
Nuclear Medicine/ Radiopharmaceuticals Market is expected to garner $8,207.5 million by 2022. The market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine.
The world radiopharmaceuticals market is expected to generate revenue of $8,207.5 million by 2022, the market is currently in its growth stage driven by increasing number of cancer cases and rising awareness about nuclear medicine.
This report studies the European nuclear medicine/radiopharmaceuticals market for the forecast period of 2015 to 2020. This market is expected to reach $1.62 Billion by 2020 from $1.09 Billion in 2015, at a CAGR of 8.2% during the forecast period (2015 to 2020).
According to #TechSci Research report, Global Nuclear Imaging Equipment Market stood at USD4054.46 million in 2020 and is expected to grow at a CAGR of 6.51% by 2026. Gain More Insight: https://bit.ly/3v29zB4 Get Sample Report: https://bit.ly/3KdYyVJ Press Release: https://bit.ly/3LGMv3y Website: https://www.techsciresearch.com/ Market Research News: https://techsciblog.com/
The Radiopharmaceutical/Nuclear Medicine Market Report offers a complete picture of industry trends and factors along with quantitative data based on historical data and from various sources. Apart from this, the report also provides the market outlook, growth, share, size, opportunity and forecast during 2019-2025. Further, the report focuses on competitive landscape including company profiles of leading key players along with industry demand, future capacities, key mergers & acquisitions, financial overview in the global market of radiopharmaceutical/nuclear medicine.
Nuclear Medicine / Radiopharmaceuticals Market report segmented the global market by Applications (Cancer/Oncology, Cardiac), By Stable Isotopes (Deuterium, C-13), [SPECT/PET Radioisotopes (Technetium, F-18)] & by Geography – Forecasting - 2017
Big Market Research “Global Contrast MediaContrast Agents Market” Size, Share, Industry Trends, Demand, Insights, Analysis, Research, Report, Opportunities, Company Profiles, Forecast to 2019. Visit for more info @ http://www.bigmarketresearch.com/global-contrast-mediacontrast-agents-2015-2019-market Contrast mediacontrast agents are chemicals used in diagnostic imaging procedures such as CT scans, MRIs, X-rays, ultrasounds, and related procedures. They enhance the internal structure of the body and provide high-quality images, which help in providing an accurate diagnosis. It is widely used in radiology, interventional radiology, and interventional cardiology.
Radiopharmaceuticals are pharmaceutical formulations comprising radioactive isotopes that are used in diagnosis and therapeutics. They are simple and small substances that contain a radioactive substance that is used in the treatment of cancer and cardiac & neurological disorders.
Castration-Resistant Prostate Cancer (CRPC) or Hormone Refractory Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after administering androgen deprivation therapy (ADT), is gaining prominence in the prostate cancer market. The global CRPC market is poised to expand at a significant pace, owing to high unmet clinical need, limited survival benefits, growing prevalence rates and fast emerging treatment modifications.
Global Radiopharmaceuticals Market, According to Data Bridge Market Research new Market report “By Type (Diagnostic, Therapeutic), Procedural Volumes (Diagnostic Procedures, Therapeutic Procedures), Application, Sources (Nuclear Reactors, Cyclotrons), End User, Geography (North America, Europe, APAC, South America, MEA)–Industry Trends and Forecast To 2024″ is projected to reach USD 9.49 billion by 2024 from USD 4.87 billion in 2016, at a CAGR of 8.7% in the forecast period 2017 to 2024. The new market report contains data for historic years 2015, the base year of calculation is 2016 and the forecast period is 2017 to 2024.
Prevalence of diseases such as cancer and cardiovascular diseases are increasing rapidly across the globe due to aging population, unhealthy food habits, and rising obesity. For instance, according to the American Heart Association, cardiovascular diseases alone accounts for 17.3 million deaths each year, which is more than the deaths caused due to cancer.
The report on United States Parkinson's Disease Drug Industry 2015 Market Research Report added by DecisionDatabases.com gives an in depth industry analysis of the market. It covers the costing, sales, revenue details and forecasts.
Global Radiopharmaceutical Theragnostics Market Forecast to 2028 – COVID-19 Impact and Analysis – by Product Type, Radioisotope, Source, Application, Indication, and End User,” the market is expected to grow from US$ 1,814.58 million in 2022 to US$ 3,441.97 million by 2028; it is estimated to grow at a CAGR of 11.3% from 2022 to 2028
The global metastatic Castration-Resistant Prostate Cancer market is expected to register a robust revenue CAGR over the forecast period owing to increased cases of prostate cancer. For instance, prostate cancer is the second most frequent cancer in males and fourth most prevalent cancer in general population.
Looking forward, the nuclear medicine equipment market value is projected to reach a strong growth during the forecast period (2022-2027). More info:- https://www.imarcgroup.com/nuclear-medicine-equipment-market
Global central nervous system biomarkers market size is expected to reach $8.02 Bn by 2028 at a rate of 9.7%, segmented as by type, safety biomarker, efficacy biomarker, validation biomarker, other types
Looking forward, the positron emission tomography (PET) market value is projected to reach a strong growth during the forecast period (2022-2027). More info:- https://www.imarcgroup.com/positron-emission-tomography-market
The global nuclear medicine equipment market size reached US$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 5.2 Billion by 2032, exhibiting a growth rate (CAGR) of 5.8% during 2024-2032. More Info:- https://www.imarcgroup.com/nuclear-medicine-equipment-market
Get World Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics - Market Opportunity and Forecast, 2014 - 2020 market research report Published by Allied Market Research. The Report is available at $4515 for Single User, and $10680 for Corporate User
According to the latest research report by IMARC Group, The global alpha emitter market size reached US$ 1,476.8 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 10,975.8 Million by 2032, exhibiting a growth rate (CAGR) of 24.22% during 2024-2032. More Info:- https://www.imarcgroup.com/alpha-emitter-market
A new report available with decisiondatabases.com on RadiopharmaceuticalsMarket which provides an in-depth analysis during the forecast period. This report focuses on top manufactures with capacity, production, price, revenue and Market share.
Breast cancer remains a formidable health challenge globally, prompting relentless efforts in early detection and treatment. Amidst the array of screening modalities, molecular breast imaging (MBI) emerges as a promising technique, offering enhanced sensitivity in detecting breast abnormalities. As the healthcare landscape evolves, it becomes crucial to delve into the molecular breast imaging market, analyzing its current state, growth trajectories, and future potential.
Looking forward, the positron emission tomography market value is projected to reach a strong growth during the forecast period (2021-2026). More info:- https://www.imarcgroup.com/positron-emission-tomography-market
The Global Contrast Media Market size is expected to reach $6.3 billion by 2025, rising at a market growth of 3.52% CAGR during the forecast period. Free Valuable Insights: https://www.kbvresearch.com/contrast-media-market/